| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 194 | 218 | 239 | 281 | 395 | 330 | 464 | 676 | 564 | 432 | 432 | 574 | 788 | 575 | 584 | 580 | 487 | 513 | 519 | 513 | 477 | 582 | 828 | 386 | 360 | 427 | 415 | 591 | 611 | 919 | 453 | 513 | 927 | 1,160 | 1,061 | 796 | 1,110 | 1,411 | 1,435 | 651 |
| Expenses | 151 | 166 | 185 | 227 | 302 | 248 | 356 | 410 | 324 | 291 | 305 | 276 | 385 | 321 | 323 | 348 | 307 | 301 | 351 | 354 | 327 | 392 | 526 | 273 | 255 | 301 | 307 | 459 | 615 | 489 | 337 | 387 | 559 | 613 | 573 | 491 | 571 | 558 | 567 | 436 |
| EBITDA | 42 | 51 | 54 | 54 | 93 | 82 | 108 | 266 | 241 | 140 | 127 | 298 | 403 | 254 | 261 | 232 | 179 | 212 | 168 | 160 | 151 | 190 | 302 | 113 | 105 | 127 | 109 | 132 | -5 | 430 | 116 | 127 | 368 | 548 | 487 | 305 | 539 | 853 | 868 | 215 |
| Operating Profit % | 21 % | 23 % | 22 % | 17 % | 23 % | 24 % | 23 % | 39 % | 43 % | 32 % | 29 % | 51 % | 50 % | 40 % | 41 % | 37 % | 33 % | 39 % | 28 % | 27 % | 28 % | 30 % | 34 % | 23 % | 23 % | 27 % | 19 % | 18 % | -3 % | 45 % | 22 % | 22 % | 38 % | 46 % | 44 % | 35 % | 47 % | 59 % | 59 % | 8 % |
| Depreciation | 13 | 13 | 13 | 13 | 12 | 13 | 14 | 14 | 14 | 15 | 16 | 17 | 18 | 18 | 20 | 21 | 22 | 22 | 22 | 25 | 31 | 28 | 29 | 30 | 30 | 34 | 35 | 36 | 38 | 40 | 42 | 42 | 41 | 44 | 44 | 44 | 56 | 44 | 46 | 47 |
| Interest | 9 | 8 | 8 | 4 | 4 | 3 | 4 | 5 | 6 | 4 | 4 | 4 | 3 | 3 | 5 | 6 | 5 | 7 | 6 | 5 | 4 | 4 | 3 | 3 | 4 | 2 | 4 | 5 | 7 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 6 | 5 | 4 | 4 |
| Profit Before Tax | 31 | 38 | 40 | 50 | 77 | 66 | 90 | 248 | 221 | 121 | 107 | 276 | 382 | 232 | 235 | 205 | 152 | 184 | 139 | 129 | 117 | 158 | 271 | 80 | 71 | 91 | 70 | 91 | -50 | 386 | 70 | 81 | 324 | 500 | 440 | 256 | 478 | 804 | 818 | 164 |
| Tax | -23 | 11 | 11 | 13 | 14 | 19 | 24 | 53 | 44 | 28 | 23 | 59 | 83 | 51 | 54 | 45 | 32 | 41 | 22 | 24 | 24 | 36 | 67 | 17 | 18 | 16 | 5 | 11 | 1 | 65 | 14 | 19 | 49 | 80 | 71 | 44 | 91 | 135 | 142 | 31 |
| Net Profit | 53 | 27 | 29 | 37 | 63 | 48 | 66 | 195 | 176 | 94 | 84 | 217 | 300 | 181 | 182 | 159 | 120 | 143 | 118 | 104 | 93 | 122 | 204 | 63 | 53 | 75 | 65 | 80 | -51 | 320 | 57 | 62 | 276 | 420 | 369 | 213 | 386 | 669 | 677 | 132 |
| EPS in ₹ | 16.41 | 1.70 | 9.05 | 2.13 | 3.86 | 2.74 | 3.79 | 11.18 | 10.10 | 5.59 | 4.82 | 12.29 | 16.26 | 9.84 | 9.89 | 8.65 | 6.59 | 7.87 | 6.55 | 5.75 | 5.17 | 6.74 | 11.12 | 3.44 | 2.91 | 4.11 | 3.57 | 4.41 | -2.77 | 22.55 | 3.11 | 3.41 | 15.11 | 23.26 | 20.60 | 11.88 | 21.56 | 37.32 | 37.81 | 7.43 |
Natco Pharma
818.15
-4.60
(-0.56%)
There are new updates from the company18 hours ago
View
Market Cap
14,653.87 Cr
EPS
77.34
PE Ratio
7.90
Dividend Yield
1.15 %
Industry
Healthcare52 Week High
1,639.00
52 Week Low
757.05
PB Ratio
2.06
Debt to Equity
0.05
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from7 analysts
Company News
View All News
Delhi High Court Rejects Roche's Plea to Block Natco Pharma on Risdiplam Patent3 days ago
The Delhi High Court has dismissed a plea by Roche, a pharmaceutical company, seeking to prevent Natco Pharma from manufacturing or selling Risdiplam, a drug used to treat spinal muscular atrophy. This decision appears to be a legal victory for Natco Pharma, allowing them to continue their operations related to Risdiplam despite Roche's patent claims.
Delhi High Court Rejects Roche's Plea Against Natco Pharma in Risdiplam Patent Case3 days ago
The Delhi High Court has dismissed a plea by Roche to block Natco Pharma regarding the patent for Risdiplam, a drug used in the treatment of spinal muscular atrophy. This ruling appears to be a setback for Roche and a potential advantage for Natco Pharma in the pharmaceutical market for this specific medication.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,707.35 | #1 4,09,650.46 | 35.22 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 54.16 | |
5,847.50 | 1,55,232.75 | 75.20 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 56.90 | |
1,457.00 | 1,17,669.50 | 24.00 | 26,520.70 | 14.17 | 4,155 | 47.38 | 51.80 | |
3,233.80 | 1,09,446.49 | 58.64 | 10,785.70 | 11.59 | 1,656 | 13.54 | 59.74 | |
2,450.90 | 1,01,118.87 | 49.78 | 10,615.60 | 19.57 | 1,942 | -16.38 | 59.91 | |
1,141.90 | 95,286.46 | #1 18.06 | 28,905.40 | 12.36 | 5,578 | 1.69 | 47.74 | |
1,997.50 | 91,194.05 | 32.14 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 47.45 | |
891.05 | 89,660.48 | 19.77 | 19,831.50 | 13.82 | 3,831 | 29.92 | 42.86 | |
1,160.25 | 67,387.51 | 19.21 | 29,559.20 | 17.55 | 3,169 | -10.04 | 53.81 | |
30,446.00 | 64,695.62 | 48.70 | 6,097.20 | 10.80 | 1,201 | 16.01 | 55.29 |
Growth Rate
Revenue Growth
46.78 %
Net Income Growth
94.09 %
Cash Flow Change
42.69 %
ROE
61.58 %
ROCE
61.92 %
EBITDA Margin (Avg.)
23.08 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 |
| Fixed Assets | 710 | 710 | 833 | 1,019 | 1,227 | 1,584 | 2,023 | 2,312 | 2,427 | 2,491 |
| Current Assets | 483 | 837 | 1,087 | 2,131 | 2,347 | 2,326 | 2,345 | 2,487 | 3,000 | 4,024 |
| Capital Work in Progress | 129 | 212 | 336 | 480 | 638 | 518 | 223 | 130 | 64 | 137 |
| Investments | 0 | 22 | 32 | 77 | 169 | 112 | 304 | 308 | 392 | 539 |
| Other Assets | 545 | 878 | 1,116 | 2,140 | 2,270 | 2,373 | 2,242 | 2,360 | 2,774 | 3,739 |
| Total Liabilities | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 |
| Current Liabilities | 414 | 493 | 627 | 592 | 729 | 685 | 526 | 710 | 683 | 973 |
| Non Current Liabilities | 119 | 28 | 38 | 47 | 83 | 118 | 143 | 135 | 101 | 80 |
| Total Equity | 851 | 1,301 | 1,653 | 3,076 | 3,491 | 3,785 | 4,123 | 4,264 | 4,874 | 5,853 |
| Reserve & Surplus | 813 | 1,261 | 1,614 | 3,035 | 3,453 | 3,737 | 4,085 | 4,227 | 4,837 | 5,817 |
| Share Capital | 33 | 35 | 35 | 37 | 37 | 36 | 37 | 37 | 37 | 36 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 2 | 90 | -1 | -2 | 7 | -9 | 6 | 85 | 21 | -62 |
| Investing Activities | -120 | -176 | -299 | -1,116 | -611 | -175 | -107 | 4 | -465 | -1,026 |
| Operating Activities | 93 | 112 | 346 | 464 | 669 | 417 | 299 | 47 | 849 | 1,212 |
| Financing Activities | 29 | 154 | -48 | 651 | -51 | -251 | -186 | 35 | -363 | -247 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 48.87 % | 48.87 % | 48.87 % | 48.86 % | 48.81 % | 48.80 % | 48.80 % | 48.82 % | 48.84 % | 49.76 % | 49.71 % | 49.71 % | 49.71 % | 49.71 % | 49.62 % | 49.62 % |
| FIIs | 0.01 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.14 % | 17.45 % | 17.51 % | 17.94 % |
| DIIs | 9.64 % | 9.16 % | 8.99 % | 9.23 % | 7.55 % | 6.75 % | 13.70 % | 14.93 % | 15.38 % | 15.02 % | 14.01 % | 11.23 % | 9.70 % | 7.87 % | 6.75 % | 5.57 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 15.66 % | 16.47 % | 16.56 % | 16.54 % | 17.48 % | 18.45 % | 20.13 % | 19.83 % | 20.24 % | 20.20 % | 19.49 % | 21.24 % | 20.60 % | 21.59 % | 22.60 % | 23.34 % |
| Others | 25.83 % | 25.47 % | 25.56 % | 25.34 % | 26.14 % | 26.00 % | 17.37 % | 16.42 % | 15.54 % | 15.02 % | 16.79 % | 17.82 % | 3.85 % | 3.39 % | 3.52 % | 3.53 % |
| No of Share Holders | 85,509 | 87,667 | 88,439 | 88,421 | 85,828 | 92,449 | 1,21,336 | 1,35,397 | 1,53,663 | 1,55,181 | 1,63,753 | 2,07,571 | 2,28,467 | 2,51,485 | 3,02,944 | 3,45,332 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 6.75 | 8.25 | 6.25 | 6.75 | 5.25 | 4.5 | 5.5 | 9.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.9 | 1.44 | 1.24 | 0.82 | 0.69 | 0.81 | 0.58 | 1.15 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
18 hours ago
18 hours agoDisclosures under Reg. 29(2) of SEBI (SAST) Regulations 20116 days ago
6 days agoDisclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Mar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Feb 24, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 21, 2025
Feb 21, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Resignation of DirectorFeb 12, 2025
Feb 12, 2025Integrated Filing (Financial)Feb 12, 2025
Feb 12, 2025Corporate Action-Board to consider DividendFeb 12, 2025
Feb 12, 2025Board Meeting Outcome for Outcome Of Board MeetingFeb 12, 2025
Feb 12, 2025Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2025
Feb 03, 2025Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter And Nine Months Ended 31St December 2024 And 3Rd Interim Dividend If AnyJan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Jan 30, 2025Order Passed By Assistant Commissioner Central Goods & Services Tax Division Dehradun.Jan 08, 2025
Jan 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Jan 07, 2025Closure of Trading WindowDec 30, 2024
Dec 30, 2024Sustainability Report For The Year 2023-2024Dec 09, 2024
Dec 09, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 04, 2024
Dec 04, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 30, 2024
Nov 30, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 27, 2024
Nov 27, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 21, 2024
Nov 21, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 21, 2024
Nov 21, 2024Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015Nov 20, 2024
Nov 20, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 19, 2024
Nov 19, 2024Announcement under Regulation 30 (LODR)-Change in ManagementNov 15, 2024
Nov 15, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2024
Nov 14, 2024Revised Record DateNov 13, 2024
Nov 13, 2024Board Meeting Outcome for Revised OutcomeNov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2024
Nov 12, 2024Corporate Action-Board to consider DividendNov 12, 2024
Nov 12, 2024Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2024Nov 12, 2024
Nov 12, 2024Board Meeting Outcome for Outcome Of The Board MeetingNov 12, 2024
Nov 12, 2024Announcement under Regulation 30 (LODR)-Change in ManagementNov 04, 2024
Nov 04, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 30, 2024
Oct 30, 2024Board Meeting Intimation for Considering The Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2024 And 2Nd Interim Dividend, If AnyOct 28, 2024
Oct 28, 2024Announcement under Regulation 30 (LODR)-Change in ManagementOct 11, 2024
Oct 11, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 07, 2024
Oct 07, 2024Technical Indicators
RSI(14)
Neutral 37.26
ATR(14)
Less Volatile 31.82
STOCH(9,6)
Neutral 66.27
STOCH RSI(14)
Overbought 90.21
MACD(12,26)
Bullish 18.03
ADX(14)
Strong Trend 32.83
UO(9)
Bearish 38.32
ROC(12)
Uptrend And Accelerating 1.39
WillR(14)
Neutral -41.30
About Natco Pharma
Natco Pharma Limited is a vertically integrated pharmaceutical company specializing in the development, manufacturing, and marketing of Finished Dosage Formulations and Active Pharmaceutical Ingredients. The company focuses on niche therapeutic areas and complex products, selling in over 40 countries. Natco operates in the Pharmaceuticals and Agro chemicals segments, with nine manufacturing facilities across India and two research centers in Telangana. They engage in contract manufacturing and have capabilities in multi-step synthesis, semi-synthetic fusion technologies, high-potency APIs, and peptides. Natco has launched several generic versions of drugs in various markets and has expanded its product portfolio in oncology, cardiology, and diabetology. The company has multiple international subsidiaries and has made strategic acquisitions to strengthen its global presence.
Website
Chairperson NameV C Nannapaneni
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
